FRAGILE X SYNDROME (FXS)
Recruiting for Phase 2 Study
We are currently recruiting for Phase 2 study to evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
The FDA has approved the U.S. IND (IND 169282) and granted Orphan Drug Designation for SPG601 for the treatment of FXS.
For Our Upcoming U.S. Clinical Trial:
NCT06413537
Status: Recruiting
Location
Cincinnati, Ohio at Cincinnati Children’s Hospital Medical Center
Contact: Dr. Craig Erickson craig@spinogenix.com
For additional information, visit ClinicalTrials.gov
